Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lobe Sciences Ltd C.LOBE

Alternate Symbol(s):  LOBEF

Healthcare Drug Manufacturers - Major
Lobe Sciences Ltd. is a Canada-based biopharmaceutical company focused on developing medicines to treat diseases with unmet medical needs. The Company, through collaborations with partners, is engaged in research and development focused on treating chronic cluster headache (an orphan disease), refractive anxiety, and sickle cell disease. In addition, the Company is commercializing Altemia, for the treatment of patients diagnosed with Sickle Cell Disease. The Company is engaged in Phase 1 and Phase 2 activities in its drug portfolios. Its subsidiaries include Eleusian Biosciences Corp., Lobe Sciences Australia Pty Ltd., and Altemia & Company, LLC.


CSE:LOBE - Post by User

Lobe Sciences Ltd
Bullboard Posts
Next >>
User Avatar Image
(2830)
•••
Post by Betteryear2on May 17, 2023 5:20pm
232 Views
Post# 35453416

Lobe Sciences Announces Commercial Distribution Agreement

Lobe Sciences Announces Commercial Distribution Agreement

VANCOUVER, British Columbia--()--Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat orphan diseases today announced it has entered into a commercial distribution agreement for the supply and distribution of Altemia™ with Pentec Health, Inc. (“Pentec Health”), a nationwide provider of clinical nutrition and specialty care services addressing complex needs for patients. Altemia™ is Lobe’s proprietary formulation of emulsified docosahexaenoic acid ethyl ester (“DHA”) concentration designed for patients with sickle cell disease (“SCD”).

Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia™ | Business Wire


Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities